ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Nutrition and Supplements
Infammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease:
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 138797" data-attributes="member: 13851"><p><strong>Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Zahra Darabi , Mina Darand , Zahra Yari , Mehdi Hedayati , Amirhosein Faghihi3, Shahram Agah </span></strong></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>Abstract</strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Objectives:</span></strong> The aim of this study was to investigate the efects of citrulline (Cit) supplementation on inflammatory markers and liver histopathology in patients with non-alcoholic fatty liver disease (NAFLD). In this clinical trial, ffty NAFLD patients were assigned to receive 2 g/day Cit or placebo for 3 months.</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results: </span></strong>At the end of study, serum high sensitive C-reactive protein (hs-CRP) and activity of nuclear factor kappa B (NF-κB) were reduced in Cit group significantly more than placebo group (P-value=0.02 and <0.01 respectively). Serum concentrations of tumor necrosis factor-α (TNF-α) was reduced in Cit group significantly more than placebo after adjusting for levels of baseline (P-value<0.001). Moreover, Cit supplementation decreased serum alanine aminotransferase (ALT) and hepatic steatosis significantly (P=0.04). Anthropometric measurements and hepatic enzymes did not change significantly in any group (P≥0.05).</p><p></p><p>In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD. Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude.</p><p></p><p></p><p></p><p></p><p><strong>Limitations </strong></p><p>One of the limitations of this study was that we did not use different dosages of Cit. We could not use higher dosages of Cit because we did not find enough evidence for their safety in human. Secondly, we could not obtain liver biopsy to estimate hepatic steatosis, and fibrosis. Liver biopsy is gold standard for the evaluation of liver fibrosis during of chronic liver diseases. However transient elastography (FibroScan®) used that provides quantitative, safely evaluation of NAFLD by scaling hepatic steatosis (CAP score) and fibrosis. Tis technique was a reliable, noninvasive way for identification of patients with significant hepatic steatosis and fibrosis. It is readily, replicability and its score has low inter- and intra-observer variability [27, 28]. Thirdly, the clinical significance of reduced inflammatory markers is not clear so additional studies are needed to see if these reductions translate to less liver- or cardiovascular-related endpoints.</p><p></p><p></p><p></p><p></p><p><strong>Conclusion</strong></p><p><strong><span style="color: rgb(184, 49, 47)">In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD.</span></strong> Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude.</p></blockquote><p></p>
[QUOTE="madman, post: 138797, member: 13851"] [B]Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial [/B] [B][COLOR=rgb(184, 49, 47)]Zahra Darabi , Mina Darand , Zahra Yari , Mehdi Hedayati , Amirhosein Faghihi3, Shahram Agah [/COLOR][/B] [B]Abstract[/B] [B][COLOR=rgb(184, 49, 47)]Objectives:[/COLOR][/B] The aim of this study was to investigate the efects of citrulline (Cit) supplementation on inflammatory markers and liver histopathology in patients with non-alcoholic fatty liver disease (NAFLD). In this clinical trial, ffty NAFLD patients were assigned to receive 2 g/day Cit or placebo for 3 months. [B][COLOR=rgb(184, 49, 47)]Results: [/COLOR][/B]At the end of study, serum high sensitive C-reactive protein (hs-CRP) and activity of nuclear factor kappa B (NF-κB) were reduced in Cit group significantly more than placebo group (P-value=0.02 and <0.01 respectively). Serum concentrations of tumor necrosis factor-α (TNF-α) was reduced in Cit group significantly more than placebo after adjusting for levels of baseline (P-value<0.001). Moreover, Cit supplementation decreased serum alanine aminotransferase (ALT) and hepatic steatosis significantly (P=0.04). Anthropometric measurements and hepatic enzymes did not change significantly in any group (P≥0.05). In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD. Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude. [B]Limitations [/B] One of the limitations of this study was that we did not use different dosages of Cit. We could not use higher dosages of Cit because we did not find enough evidence for their safety in human. Secondly, we could not obtain liver biopsy to estimate hepatic steatosis, and fibrosis. Liver biopsy is gold standard for the evaluation of liver fibrosis during of chronic liver diseases. However transient elastography (FibroScan®) used that provides quantitative, safely evaluation of NAFLD by scaling hepatic steatosis (CAP score) and fibrosis. Tis technique was a reliable, noninvasive way for identification of patients with significant hepatic steatosis and fibrosis. It is readily, replicability and its score has low inter- and intra-observer variability [27, 28]. Thirdly, the clinical significance of reduced inflammatory markers is not clear so additional studies are needed to see if these reductions translate to less liver- or cardiovascular-related endpoints. [B]Conclusion [COLOR=rgb(184, 49, 47)]In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD.[/COLOR][/B] Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Nutrition and Supplements
Infammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease:
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top